78% of Americans think vaccine approval process is too politics-driven

Most Americans think political motivations are influencing the FDA’s vaccine approval process more than science is, according to a recent survey conducted by STAT and the Harris Poll.

Advertisement

From Aug. 25-27, researchers collected responses from 2,067 American adults to gain insight about the public’s emerging concern that the White House will rush to approve a COVID-19 vaccine before ensuring it is completely safe.

Here are some of the survey’s notable findings:

  • Seventy-eight percent of respondents reported feeling worried the COVID-19 vaccine approval process is more influenced by politics than science, with 72 percent of Republicans and 82 percent of Democrats expressing such concerns.
  • Sixty-seven percent of respondents reported they would get a COVID-19 vaccine as soon as one becomes available. Sixty-two percent of respondents reported they would get one if it becomes available before the election, and 71 percent reported they would receive one nine months after it becomes available.
  • Seventy-two percent of respondents reported doubting that a COVID-19 vaccine will be approved by 2021.
  • Sixty-eight percent of respondents reported believing the FDA will only endorse a vaccine that is safe.
  • Forty-six percent of respondents reported trusting the White House to provide accurate information about COVID-19 vaccine developments, with 71 percent of Republicans and 28 percent of Democrats responding that they believe the White House updates.
  • Forty-seven percent of respondents reported feeling confident in news media to provide accurate information about COVID-19 vaccine developments, and 29 percent of respondents reported feeling confident in social media platforms to do the same.

More articles on pharmacy:
‘Most favored nations’ executive order unlikely to save money for most Americans, analysis finds
DIY COVID-19 vaccines could dishearten trust in science, experts warn
FDA extends remdesivir’s emergency use authorization to all hospitalized COVID-19 patients

Nestle acquires Aimmune Therapeutics for $2.6B

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.